Internationalized domain name

Keen360 Released Keen Life Sciences for Pharma, Biotech & Medical Device Industries to Extend Creatio's No-code Platform Capabilities

Thursday, October 14, 2021 - 1:44pm

The pre-configured application offers enterprise-caliber functionality and security, extending the no-code Creatio platform capabilities to allow professionals engaged in commercial operations in the life sciences industry to power-up their day-to-day operations.

Key Points: 
  • The pre-configured application offers enterprise-caliber functionality and security, extending the no-code Creatio platform capabilities to allow professionals engaged in commercial operations in the life sciences industry to power-up their day-to-day operations.
  • Keen Life Sciences is well suited for both well-established companies that are relying on mature commercial teams and rapidly-growing ventures that areemerging from clinical trials and launching their commercial teams.
  • The solution offers the full range of functionality usually found in the complex and expensiveapplications that are built on the SFDC platform.
  • Key Keen Life Sciences features:
    HCO & HCP profiles:capture and maintain the range of domain-specific information about your HCOs and HCPs.

Nanox to Announce Zebra Medical Vision Secures 8th 510K FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of its Population Health Offering

Monday, September 27, 2021 - 1:30pm

NEVE ILAN, Israel, Sept. 27, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Zebra Medical Vision secures 8th 510K FDA clearance for its Coronary Artery Calcium (CAC) solution as part of its population health offering.

Key Points: 
  • NEVE ILAN, Israel, Sept. 27, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Zebra Medical Vision secures 8th 510K FDA clearance for its Coronary Artery Calcium (CAC) solution as part of its population health offering.
  • On August 10th, 2021 Nanox announced that it had entered into an acquisition agreement via merger with Zebra Medical Vision LTD.
  • Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications.
  • This press release may contain forward-looking statements that are subject to risks and uncertainties.

Nanox to Announce Zebra Medical Vision Secures 8th 510K FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering

Monday, September 27, 2021 - 1:30pm

NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Zebra Medical Vision secures 8th 510K FDA clearance for its Coronary Artery Calcium (CAC) solution as part of its population health offering.

Key Points: 
  • NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Zebra Medical Vision secures 8th 510K FDA clearance for its Coronary Artery Calcium (CAC) solution as part of its population health offering.
  • On August 10th, 2021 Nanox announced that it had entered into an acquisition agreement via merger with Zebra Medical Vision LTD.
  • Please check Zebra Medical Visions announcement here: https://www.businesswire.com/news/home/20210927005367/en/Zebra-Medical-V...
    Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications.
  • This press release may contain forward-looking statements that are subject to risks and uncertainties.

Zebra Medical Vision Secures 8th FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering

Monday, September 27, 2021 - 12:30pm

Zebra Medical Vision , the deep-learning medical imaging analytics company, announces today its eighth FDA 510(k) clearance for its cardiac solution, "HealthCCSng" which has already received a CE mark.

Key Points: 
  • Zebra Medical Vision , the deep-learning medical imaging analytics company, announces today its eighth FDA 510(k) clearance for its cardiac solution, "HealthCCSng" which has already received a CE mark.
  • View the full release here: https://www.businesswire.com/news/home/20210927005367/en/
    Zebra Medical Vision secures 8th FDA clearance for its Coronary Artery Calcium (CAC) solution as part of its population health offering (Photo: Zebra-Med)
    Approximately 90% of the annual $3.5 Trillion healthcare spending is allocated towards chronic disease management.
  • The company remains firmly committed to its robust product roadmap, which is designed to advance population health and preventative care.
  • Zebra Medical Visions solutions integrate into existing radiology workflows, including primary care physicians and specialists in cardiology, bone health and others.

MCRA Expands Evidence Generation Service Line to Ensure Early Stakeholder Engagement for Optimal Product Adoption

Wednesday, September 15, 2021 - 6:18pm

With over 20 years of experience in clinical pharmacy, reimbursement and market access, Dr. Stevens has focused her career on understanding stakeholder needs and developing evidence for optimal product positioning and market adoption.

Key Points: 
  • With over 20 years of experience in clinical pharmacy, reimbursement and market access, Dr. Stevens has focused her career on understanding stakeholder needs and developing evidence for optimal product positioning and market adoption.
  • MCRA's Vice President, Reimbursement, Health Economics & Market Access, Tonya Dowd said "I'm thrilled to have Dr. Stevens on our team.
  • Dr. Stevens's role is the linchpin to achieve successful market adoption and ultimately, patient access to our clients' valuable technologies."
  • About MCRA, LLC: MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm.

Sphere Joins with Saina Health to Enable Secure Patient Payments

Monday, September 13, 2021 - 12:11pm

NASHVILLE, Tenn., Sept. 13, 2021 /PRNewswire/ -- Sphere ,a leading provider of end-to-end integrated healthcare payments and security software, today announced it has joined with Saina Health to enable secure payment acceptance through its InstaHealth platform.

Key Points: 
  • NASHVILLE, Tenn., Sept. 13, 2021 /PRNewswire/ -- Sphere ,a leading provider of end-to-end integrated healthcare payments and security software, today announced it has joined with Saina Health to enable secure payment acceptance through its InstaHealth platform.
  • By teaming up with Sphere, Saina Health extends its industry leading secure payment acceptance through its InstaHealthTM platform to protect patient payment data end-to-end.
  • "Sphere is excited to partner with innovative healthcare companies that elevate the patient experience and provider workflow," said Anthony Lucatuorto, President, Integrated Health & Payments at Sphere.
  • Health iPASS, a fully integrated suite of patient engagement software solutions to streamline the patient experience while driving patient payment yield.

Cognito Therapeutics Announces Formation of Payor Advisory Board

Wednesday, September 8, 2021 - 1:00pm

Cognito Therapeutics , a Phase 3-ready disease-modifying therapeutics company using non-invasive neuromodulation to reduce or halt the progression of neurodegenerative diseases, announced today the formation of a first-in-category Payor Advisory Board to enable day one payor coverage upon approval and insure timely and broad patient access to Cognitos breakthrough treatment for Alzheimers.

Key Points: 
  • Cognito Therapeutics , a Phase 3-ready disease-modifying therapeutics company using non-invasive neuromodulation to reduce or halt the progression of neurodegenerative diseases, announced today the formation of a first-in-category Payor Advisory Board to enable day one payor coverage upon approval and insure timely and broad patient access to Cognitos breakthrough treatment for Alzheimers.
  • The Payor Advisory Board comprises seven payors and integrated delivery networks, collectively managing approximately 119 million lives.
  • Cognito Therapeutics recognizes the need to engage payors and providers earlier in the process of developing new therapeutics for large population with high unmet need like Alzheimers Disease.
  • Cognito Therapeutics is a Phase 3-ready disease-modifying therapeutics company using non-invasive neuromodulation to reduce or halt the progression of neurodegenerative diseases, including Alzheimers disease.

Internet Has 367.3 Million Domain Name Registrations at the End of the Second Quarter of 2021

Thursday, September 2, 2021 - 8:25pm

VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the second quarter of 2021 closed with 367.3 million domain name registrations across all top-level domains (TLDs), an increase of 3.8 million domain name registrations, or 1.0%, compared to the first quarter of 2021.1,2 Domain name registrations have decreased by 2.8 million, or 0.7%, year over year.1,2

Key Points: 
  • VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the second quarter of 2021 closed with 367.3 million domain name registrations across all top-level domains (TLDs), an increase of 3.8 million domain name registrations, or 1.0%, compared to the first quarter of 2021.1,2 Domain name registrations have decreased by 2.8 million, or 0.7%, year over year.1,2
    The .com and .net TLDs had a combined total of 170.6 million domain name registrations in the domain name base3 at the end of the second quarter of 2021, an increase of 2.6 million domain name registrations, or 1.5%, compared to the first quarter of 2021.
  • The .com and .net TLDs had a combined increase of 8.5 million domain name registrations, or 5.2%, year over year.
  • As of June 30, 2021, the .com domain name base totaled 157.0 million domain name registrations, and the .net domain name base totaled 13.6 million domain name registrations.
  • New .com and .net domain name registrations totaled 11.7 million at the end of the second quarter of 2021, compared to 11.1 million domain name registrations at the end of the second quarter of 2020.

Acumed | OsteoMed Launches the PFX Choice™ Program for Hospitals, IDNs, GPOs, and ASCs

Friday, August 20, 2021 - 12:05pm

The Acumed | OsteoMed PFX Choice program is designed to help.

Key Points: 
  • The Acumed | OsteoMed PFX Choice program is designed to help.
  • "PFX Choice offers flexibility and customization, including best-in-class pricing, scalability, and service," said Aaron Greer, Director of National Accounts at Acumed | OsteoMed.
  • Acumed | OsteoMed offers robust education and training programs for surgeons and OR staff, including cadaveric, surgeon-to-surgeon, and surgeon thought leader training.
  • * The Acumed | OsteoMed portfolio includes comprehensive solutions for CMF, Hand & Upper Extremity, Foot & Ankle, Tendon & Ligament repair, and Orthobiologics.

In an up-to $200M Acquisition by Nanox, Zebra Medical Vision Brings Its AI to Reimagine Radiology Globally

Tuesday, August 10, 2021 - 2:56pm

As a result of the acquisition, the medical imaging pioneers will leverage Zebra-Meds industry-leading team, cutting-edge AI technology and cloud capabilities, and unprecedented regulatory framework to form the next-generation medtech juggernaut.

Key Points: 
  • As a result of the acquisition, the medical imaging pioneers will leverage Zebra-Meds industry-leading team, cutting-edge AI technology and cloud capabilities, and unprecedented regulatory framework to form the next-generation medtech juggernaut.
  • Zebra Medical Vision has always operated with the goal of expanding the use of AI in medical imaging to improve health outcomes for patients worldwide, says Zohar Elhanani, CEO of Zebra Medical Vision.
  • Screening populations to detect and treat chronic disease early on, while establishing new care pathways, has significantly improved treatment outcomes.
  • Zebra Medical Vision has raised $52 million in funding to date, and was named a Fast Company Top-5 AI and Machine Learning company.